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Identifying single nucleotide polymorphisms (SNPs) that influence chemotherapy disposition may 
help to personalize cancer treatment and limit toxicity. Genome-wide approaches are unbiased, 
compared with candidate gene studies, but usually require large cohorts. As most chemotherapy is 
given cyclically multiple blood sampling is required to adequately define drug disposition, limiting 
patient recruitment. We found that carboplatin and paclitaxel disposition are stable phenotypes in 
ovarian cancer patients and tested a genome-wide association study (GWAS) design to identify SNPs 
associated with chemotherapy disposition. We found highly significant SNPs in ABCC2, a known 
carboplatin transporter, associated with carboplatin clearance (asymptotic P = 5.2 × 106, empirical 
P = 1.4 × 10−5), indicating biological plausibility. We also identified novel SNPs associated with 
paclitaxel disposition, including rs17130142 with genome-wide significance (asymptotic P = 2.0 × 10−9, 
empirical P = 1.3 × 10−7). Although requiring further validation, our work demonstrated that GWAS 
of chemotherapeutic drug disposition can be effective, even in relatively small cohorts, and can be 
adopted in drug development and treatment programs.
Large inter-individual variation in drug disposition has been reported for most chemotherapeutic drugs at stand-
ard dosing schedules1, including paclitaxel and carboplatin2,3. For women with advanced epithelial ovarian cancer 
(EOC), the standard of care is cytoreductive surgery and six cycles of paclitaxel and carboplatin chemotherapy4,5. 
Despite a high initial response rate (~75%), the median progression-free survival is between 16–21 months and 
there is a wide range in median overall survival reported, between 31–57 months6. There is also significant var-
iability in chemotherapy side effects, some with a genetic component. For example, more haematological and 
neurological toxicities have been reported in Asian ovarian cancer patients compared to European patients5,7,8.
It may be hypothesized that variation in drug disposition is a contributing factor in variable treatment effects 
in EOC. There have been several well-studied associations between germline genetic variants and chemother-
apeutic drug toxicity, leading to the inclusion of pharmacogenomic information in the US Food and Drug 
Administration (FDA) advice to prescribers for drugs including Irinotecan and Capecitabine9–11. In examples to 
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date, these genetic variants were identified using a candidate gene approach, focusing on genes involved in drug 
metabolism. However, this approach requires a priori biological knowledge and will not reveal novel biomarkers 
or associations. The aim of this study was to identify novel germline genetic variants that influence carboplatin 
and paclitaxel disposition in ovarian cancer patients using a genome-wide association study (GWAS) approach.
Results
Patient selection and characteristics. The clinical characteristics of the two patient cohorts in this study, 
the Australian and Dutch cohorts, were similar, except that Dutch patients had higher body weight (due in part to 
increased height), resulting in higher paclitaxel doses (Table 1). The median creatinine level was lower (P = 0.002) 
in the Australian cohort (although both were within normal range), resulting in higher estimated glomerular 
filtration rate (GFR) (P = 0.003).
A significant inter-individual, but small intra-individual variability in paclitaxel and carboplatin 
disposition. The paclitaxel and carboplatin pharmacokinetic (PK) parameters were summarized in Tables 2 
and 3, respectively. These results were consistent with published data12,13. Significant inter-individual variability 
was observed in paclitaxel TC>0.05 (Time of paclitaxel concentration > 0.05 µmol/L) (>2-fold) and carboplatin 
clearance (~5-fold). In contrast, there were no statistically significant differences of paclitaxel TC>0.05 (P = 0.595) 
(Fig. 1a) and carboplatin clearance (P = 0.682) (Fig. 1b) between two treatments in the seven Australian patients 
with PK sampling performed at both cycle one and three. These results demonstrated that chemotherapeutic drug 
disposition was a stable phenotype in individuals (at least over a six-week period), and supported the hypothesis 
that there is a genetic component underlying drug disposition.
Correlations between drug disposition and hematological toxicity. Hematological assessment after 
the first cycle of chemotherapy was performed in 49 Australian patients receiving combination chemotherapy. 
Paclitaxel TC>0.05 was associated with relative neutropenia (Fig. 2a) (R = 0.436, P = 0.002) but not with relative 
thrombocytopenia (Fig. 2b) (R = 0.247, P = 0.087). On the other hand, the correlation between carboplatin clear-
ance and relative neutropenia was not statistically significant (Fig. 2c) (R = −0.144, P = 0.324), but there was a 
statistically significant inverse correlation between carboplatin clearance and relative thrombocytopenia (Fig. 2d) 
(R = −0.336, P = 0.018) by simple linear regression analysis. These findings are in accordance with previous pub-
lications14–16 and confirmed paclitaxel TC>0.05 is a good predictive marker for severe neutropenia, whereas carbo-
platin clearance predicts thrombocytopenia, using the population pharmacokinetic modelling we applied.
GWAS identified novel polymorphisms associated with paclitaxel exposure. We found that 
~27% variability in paclitaxel TC>0.05 was accounted for by paclitaxel dose, GFR and AST (aspartate amino 
transaminase), therefore tested each SNP for its association with paclitaxel TC>0.05 without and with adjust-
ment for these three covariates. Thirty-seven patients of European ethnicity and 14 of Asian ethnicity from the 
Normal Median (range)
Parange Australian cohort Dutch cohort
Number of patients 61 35
Ancestry
   European 43 (70.5%) 35 (100%)
   Asian 14 (23.0%) 0 (0.0%)
Others 4 (6.6%) 0 (0.0%)
Treatment
   Carboplatin + paclitaxel 55 (90.2%) 35 (100%)
   Carboplatin only 6 (9.8%) 0 (0.0%)
Pharmacokinetic sampling
   Cycle 1 61 (100%) N/Ab
   Cycle 3c 7 (11.5%)
Age 56 (19–74) 57 (38–74)
Height (cm) 161 (148–174) 167 (150–179) 0.918
Weight (kg) 64 (36–120) 75 (53–111) 0.015
Total bilirubin (µmol/L) ≤20 6 (2–13) 6 (6–13) 0.430
Albumin (g/L) 35–50 40 (20–49) N/Ad N/A
Alanine amino transaminase (U/L) ≤47 28 (6–159) 22 (7–55) 0.779
Aspartate amino transaminase (U/L) ≤45 40 (14–242) 24 (17–45) 0.016
Creatinine (µmol/L) 55–105 60 (42–165) 69 (45–118) 0.002
Glomerular filtration rate (mL/min) 90–120 80 (22–143) 70 (36–107) 0.003
Table 1. Demographic and biological characteristics of patient cohorts. aP-values were based on independent 
sample median test. bPaclitaxel sampling was performed in different treatment cycles in the Dutch cohort. 
cSeven patients had carboplatin and paclitaxel sampling performed during both cycle 1 and cycle 3. dAlbumin 
level results were available from only eight patients in the Dutch cohort.
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Australian cohort, and 35 patients of European ethnicity from the Dutch cohort were available for analysis. Six 
Dutch patients were missing AST values therefore 29 were included in the adjusted analysis.
Manhattan plots, showing SNP association P-values from the meta-analysis (-log10(p)) against genomic 
position, in unadjusted and adjusted analyses are presented in Fig. 3a and b. The genomic control parameters 
were 1.01 and 1.02 respectively, suggesting that there was little population substructure or other artefacts. In 
the unadjusted GWAS (Fig. 3a), 25 SNPs were found to be associated with paclitaxel TC>0.05 with P < 1 × 10−5 
(Supplementary Table S1). The SNP with the highest statistical significance was rs17130142. The P value from 
meta-analysis was 1.8 × 10−7. We ran 107 permutations to correct for the asymptotically approximated results 
and empirical p-value remained unchanged. In the adjusted analysis (Fig. 3b), 19 SNPs were associated with pacl-
itaxel TC>0.05 with P < 1 × 10−5 (Supplementary Table S2). Rs17130142 remained the most statistically significant 
polymorphism.
Rs17130142 is an intergenic polymorphism on chromosome 1 (Fig. 3c). It has a minor allele frequency (MAF) 
~5% in European patients (7% and 3% in the Australian and Dutch cohort respectively), but was monomor-
phic in the 14 Asian patients. The minor allele A was associated with increased paclitaxel TC>0.05 in European 
patients from both the Australian cohort (effect = 8.58, P = 6.5 × 10−6) and the Dutch cohort (effect = 18.24, 
P = 7.7 × 10−5). In the meta-analysis, it met the criteria for genome-wide statistical significance (P = 2.0 × 10−9). 
Median (range)
P - value aAustralian cohort Dutch cohort
Dose (mg) 290 (220–350) 320 (230–390) <0.001
Infusion time (h) 3.2 (2.8–3.9) 3.4 (2.5–4.5) 0.224
Infusion rate (mg/h) 90 (71–110) 98 (63–135) 0.153
CL at the end of infusion (L/h) 9.9 (5.2–17.3) 11.2 (5.2–20.5) 0.209
TC>0.05 (h) 30.3 (21.0–47.3) 27.8 (20.5–46.0) 0.094
AUC0-24 (mg/L*h) 16.4 (10.5–26.1) 15.3 (11.3–27.1) 0.402
Cmax (mg/L) 4.9 (3.2–7.5) 4.9 (3.0–8.9) 1.000
Table 2. Paclitaxel pharmacokinetic parameters. aP-values were based on the independent sample median 
test. Abbreviations: CL, clearance; TC>0.05, time of paclitaxel concentration >0.05 µmol/L; AUC0-24, area under 
concentration-time curve of the first 24 hours; Cmax, maximum paclitaxel concentration.
Parameters Median Range
Dose (mg) 680 300–900
CL (L/h) 7.5 2.8–12.9
V (L) 15.5 4.0–32.0
Cmax (mg/L) 38.0 18.6–57.1
AUC0–24 (mg/L*h) 89.9 60.1–129.4
Table 3. Carboplatin pharmacokinetic parameters. Abbreviations: CL, clearance; V, volume of distribution; 
Cmax, maximum concentration; AUC0-24, area under concentration-time curve of the first 24 hours.
Figure 1. Pharmacokinetic parameter intra-individual variability. (a) Time of paclitaxel concentration >0.05 
µmol/L (TC>0.05) and (b) carboplatin clearance from cycle one and three of chemotherapy in seven Australian 
patients, analysed by paired sample t test. The patients are ordered according to increasing carboplatin clearance 
rate.
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Due to the small number of heterozygous patients (5 from 37 Australian patients and 2 from 29 Rotterdam 
patients), the empirical p-value after 107 permutations dropped to 1.3 × 10−7.
ABCC2 polymorphisms associated with carboplatin clearance. Consistent with published data17, 
we found GFR accounted for >90% variability in carboplatin clearance. Therefore, we tested association between 
each SNP and carboplatin clearance unadjusted and adjusted for GFR. 42 European patients (1 removed due to 
low genotyping call rate) and 14 Asian patients in the Australian cohort were included in meta-analysis weighted 
by sample size.
The genomic control parameters for the unadjusted and adjusted analysis were 1.00 and 1.03 respectively. 
In the unadjusted GWAS (Fig. 4a), four SNPs were found to be associated with carboplatin clearance with 
P < 1 × 10−5 (Supplementary Table S3). After adjusting for GFR, these associations were not statistically signif-
icant (P > 0.05), suggesting the putative associations found between these SNPs and carboplatin clearance were 
due to associations with GFR.
However, in the adjusted GWAS (Fig. 4b), 17 SNPs were found to be associated with carboplatin clearance 
with P < 1 × 10−5 (Supplementary Table S4). Of highest statistical significance was rs7230264 (P = 8.7 × 107), 
a SNP that lies within an intron of RP11-739N10, a long intergenic non-coding RNA (lincRNA) of unknown 
function on chromosome 18. The minor allele A was associated with decreased carboplatin clearance and has a 
frequency of 12% in European patients and 25% in Asian patients.
Interestingly, a cluster of SNPs in complete linkage disequilibrium (r2 = 1) around ABCC2 were found to be 
putatively associated with carboplatin clearance in 42 patients with European ancestry (P = 5.2 × 10−6) (Fig. 4c). 
They are monomorphic in 14 patients with Asian ancestry (Supplementary Table S4). Located on chromo-
some 10q24, ABCC2 encodes a carboplatin efflux transporter ABCC2 (also known as multiple resistant protein 
2 - MRP2) (see the locusZoom plot18 in Fig. 4c). Due to the small number of heterozygous patients for these 
SNPs (N = 3), we also ran 107 permutations to correct for the asymptotically approximated results. The empir-
ical p value from the permutation was 1.4 × 10−5. The details of the four SNPs in ABCC2 are summarised in 
Table 4. Patients carrying the variant alleles at these SNPs had decreased carboplatin clearance (effect = −1.21; 
Supplementary Table S4), potentially leading to a higher carboplatin systemic exposure.
Figure 2. Associations between paclitaxel and carboplatin disposition and haematological toxicities. (a) 
Association between time of paclitaxel concentration >0.05 µmol/L (TC>0.05) and relative neutropenia; (b) 
association between TC > 0.05 and relative thrombocytopenia; (c) association between carboplatin clearance 
and relative neutropenia and (d) association between carboplatin clearance and relative thrombocytopenia, 
analysed by simple linear regression analysis in 49 Australian patients receiving paclitaxel and carboplatin 
combination chemotherapy.
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Discussion
Inherited genetic variation has an impact on drug absorption, metabolism and excretion, and therefore on phar-
macodynamics. Identifying SNPs that influence chemotherapy disposition may help to personalize individual 
treatment. While GWAS has the advantage of being unbiased, they usually require a large sample size. Since most 
cytotoxic drugs have a short half-life and are given cyclically, multiple blood samples are required to adequately 
define drug disposition and systemic exposure. This tends to limit patient sample sizes in pharmacokinetic stud-
ies. Having demonstrated that carboplatin and paclitaxel disposition is a stable phenotype within an individual, 
we performed two separate GWAS of paclitaxel and carboplatin disposition and identified novel inherited genetic 
variants associated with drug disposition in ovarian cancer patients.
In the paclitaxel GWAS, we identified a novel polymorphism associated with paclitaxel TC>0.05 with 
genome-wide significance. Rs17130142 is located on chromosome 1 between LOC100505768 (distance = 402 kb) 
and PKN2 (Protein kinase N2) (distance = 910 kb). PKN2 encodes a transmembrane serine/threonine protein 
kinase. It plays a role in cell cycle progression and cytokinesis19. Being an intergenic polymorphism, the function 
and effects of rs17130142 are unknown, but it may regulate upstream or downstream genes and affect gene splic-
ing, transcription factor binding, messenger RNA degradation, or the sequence of non-coding RNA20,21. Further 
fine mapping and functional analysis to determine the target gene and underlying mechanism is warranted.
In the adjusted carboplatin GWAS, four ABCC2 SNPs in complete linkage disequilibrium were associated with 
carboplatin clearance. ABCC2 is localized in the apical luminal membrane of polarized epithelial cells of several 
excretory organs including liver, intestine and kidney22. It has an important function in the biliary excretion of 
endogenous metabolites. ABCC2 transports drug conjugated to glutathione including platinum agents23 and also 
exports many unconjugated substances24. ABCC2 polymorphism has been found associated with response and 
survival in patients with gastric25, oesophageal26, ovarian27, non-small cell cancer lung cancer28,29. Among the 
four SNPs, rs8187710 (4544 G > A) in exon 32 is non-synonymous leading to a cysteine to tyrosine transition 
Figure 3. Paclitaxel GWAS. Manhattan plots of paclitaxel disposition GWAS (a) unadjusted and (b) adjusted 
for paclitaxel dose, glomerular filtration rate (GFR) and aspartate amino transaminase (AST); (c) LocusZoom 
plot for rs17130142 from the adjusted paclitaxel GWAS. The color shading indicates the strength of LD (r2) 
from the reference of 1000 Genome Project (CEU samples) between the corresponding SNP and the top SNP, 
rs17130142. The red horizontal line indicates the genome-wide significance threshold of P = 5 × 10−8; the blue 
line is the threshold for putative association (P = 10−5).
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at position 1515 in the last cytoplasmic loop of ABCC2. In stably transfected human embryonic kidney cells 
(HEK293), a 4544 A clone showed higher accumulation of lopinavir, calcein and carboxyfluorescein diacetate 
(ABCC2 substrates) as well as reduced ABCC2 mediated efflux of lopinavir compared with a 4544G clone30. 
Increased risks of acute anthracycline-induced cardiac toxicity31 and congestive heart failure32 have also been 
reported in patients carrying the minor allele at rs8087710, who received doxorubicin chemotherapy, another 
ABCC2 substrate. As there is no physiological evidence of ABCC2 expression in the heart, increased cardiac 
toxicity could be caused by a reduced biliary elimination of doxorubicin, which normally accounts for 50% of its 
disposition33. Further supporting our findings, the major G allele of rs8187710 has been reported to be associated 
with inferior overall survival in 188 platinum-treated stage IV non-small-cell lung cancer (ASCO annual meet-
ing 2012, abstract number 7586), presumably due to increased platinum clearance. These reports are in agree-
ment with our finding that minor alleles of these ABCC2 SNPs are associated with reduced ABCC2 transporter 
function, leading to decreased carboplatin clearance. This could be clinically relevant for platinum toxicity and 
Figure 4. Carboplatin GWAS. Manhattan plots of carboplatin clearance GWAS (a) unadjusted and (b) adjusted 
for glomerular filtration rate; (c) LocusZoom plot for ABCC2 loci from adjusted carboplatin GWAS. The colour 
shading indicates the strength of LD (r2) from the reference of 1000 Genome Project (CEU samples) between 
the corresponding SNP and the labelled SNP, rs8187710. The red horizontal line indicates the genome-wide 










rs17222723 exon 25 3702 3563 T → A GTG → GAG 1188 Val → Glu
rs8187707 exon 31 4627 4488 C → T CAC → CAT 1496 His = His
rs8187710 exon 32 4683 4544 G → A TGC → TAC 1515 Cys → Tyr
rs11816708 intergenic N/A N/A T → C N/A N/A N/A
Table 4. Genetic polymorphisms in ABCC2 associated with carboplatin clearance in the adjusted carboplatin 
GWAS. Abbreviations: Val, valine; Glu, glutamate; His, histidine; Cys, cysteine; Tyr, tyrosine
www.nature.com/scientificreports/
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response. Although fine mapping and functional analyses have not been performed, ABCC2 is an obvious candi-
date and it is reasonable to assume that it is the functionally relevant target of this GWAS finding.
Additional SNPs were found to be associated with carboplatin clearance in the adjusted GWAS. Among the 
SNPs listed in Supplementary Table S4, rs7230264 located in lincRNA RP11-739N10 on chromosome 18 was of 
the highest statistical significance. LincRNAs have been implicated in a wide range of cellular processes including 
gene transcription regulation34, post-transcriptional regulation35 and epigenetic regulation36. The role of lincRNA 
RP11-739N10 in relation to carboplatin clearance remains to be determined.
GWAS have been used to identify common DNA sequence variants that are associated with susceptibil-
ity to over 250 complex disease traits, using very large sample size of thousands to hundreds of thousands of 
patients. With few exceptions, the odds ratios (ORs) for the effects are typically in the range of 1.05 to 1.15. In 
contrast, GWAS studies of drug efficacy or safety with small patient cohorts, with some ranging from only 20 to 
80 patients37–40, have revealed a substantial number of unanticipated and often striking signals. The large effects 
identified in pharmacogenomics studies are likely due to the lack of an evolutionary response to modern exoge-
nous agents. Unlike genes associated with common disease, which are located on haplotype blocks that have been 
selected to overcome environmental influences and selection pressure over thousands if not millions of years, the 
genome has had very little time to adapt to exposure to prescription medications41. This could explain our signif-
icant findings in a relatively small patient cohort.
In conclusion, our GWAS approach identified SNPs putatively associated with carboplatin and paclitaxel 
disposition. Examination of the functional characteristics of the SNPs may provide novel pharmacogenomic 
biomarkers for personalized ovarian cancer treatment. More importantly, our findings support that GWAS of 
chemotherapeutic drug disposition can be effective even when performed in a relatively small number of samples 
and can be used to improve the drug candidate pipeline and boost the efficacy while limiting the toxicity of med-
ications already in use. As genotyping and sequencing costs continue to decline, every effort should be made to 
incorporate comprehensive, unbiased pharmacogenomic analyses in strategies to optimise treatment outcome.
Materials and Methods
Patient population. Patients with EOC receiving paclitaxel and carboplatin (N = 55) or single agent carbo-
platin (N = 6), were recruited between 2009 and 2012 from Westmead Hospital and Royal Prince Alfred Hospital, 
Sydney, Australia. Key inclusion criteria were histologically or cytologically confirmed EOC; ECOG ≤ 2; adequate 
organ function and no concurrent use of moderate or strong cytochrome P450 and ATP-binding cassette trans-
porter (ABC transporter) inhibitors or inducers. An independent paclitaxel pharmacokinetic (PK) cohort of 35 
EOC patients was recruited through the Erasmus MC - Cancer Institute, Rotterdam, the Netherlands. This study 
was approved by the Medical Ethics Review Board Erasmus MC in the Netherlands and the Sydney West Area 
Health Service Human Research Ethics Committee (now known as the Western Sydney Local Health District 
Human Research Ethics Committee) in Australia. All experiments were performed in accordance with relevant 
guideline and regulations. Written informed consent was obtained from each patient.
Cremophor EL formulated paclitaxel (175 mg/m2) was administered intravenously (i.v.) over a planned 3-hour 
infusion. This was immediately followed by a 1-h infusion of carboplatin (AUC 5-6 mg/mL*min) in patients 
receiving combination chemotherapy. The carboplatin doses were calculated according to the method described 
by Calvert42 and glomerular filtration rate (GFR) was estimated using the Cockcroft-Gault formula43.
Pharmacokinetic blood sampling and bioanalysis. Blood samples for PK analyses were taken in 
10-mL ETDA tubes during the cycle one treatment for all patients. In consenting participants from the Australian 
cohort, additional PK blood samples were also collected during cycle three of chemotherapy (N = 7). In the 
Australian cohort, blood sampling was taken immediately before the start, 1.5 hours after the start, at the end 
of paclitaxel infusion, at the end of carboplatin infusion, ~2–3 hours after the end of carboplatin infusion and ~ 
21 hours after the end of paclitaxel infusion respectively, with the precise time for each blood sampling recorded. 
In the Dutch cohort, blood sampling was performed before the start, 1.5 hours after the start, at the end and 
~2–3 hours after the end of paclitaxel infusion.
Whole blood was centrifuged immediately for 10 minutes at 3,000 rpm (1,500 g) at 4 °C. For paclitaxel PK anal-
ysis, plasma was collected and stored at -80 °C. For carboplatin PK analysis, plasma was immediately transferred 
and centrifuged through a 30-kDa cut-off Amicon® ultrafiltrate filter (Millipore, Billerica, Massachusetts USA) 
for 15 min at 3,000 rpm at 20 °C. The preparation of ultrafiltrate was done immediately after blood collection to 
prevent the decrease of free carboplatin level due to ex vivo binding of carboplatin to plasma proteins and eryth-
rocytes. All specimens were stored in cryovials at -80 °C until analysis.
Paclitaxel concentrations were measured using liquid chromatography - tandem mass spectrometry (LC-MS/
MS) (Waters Chromatography B.V, Etten-Leur, the Netherlands) at the Laboratory of Translational Pharmacology, 
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands44. Carboplatin 
levels were measured using a Varian 820 inductively coupled plasma mass spectrometry (ICP-MS) connected to 
a Varian SPS 3 auto-sampler as previously described with minor modification45 at Trace Inorganics Laboratory, 
Division of Analytical Laboratories, Sydney West Area Health Service, Australia.
Population pharmacokinetic modelling. The paclitaxel and carboplatin concentration-time data were 
analysed using the non-linear, mixed-effects modelling program (NONMEM) version VI (ICON, Hanover, MD, 
USA). R (version 2.13 or above, R programming) and PsN (Perl Speaks for NONMEM, Uppsala) were used for 
data preparation, graphical analysis, model diagnostics. The first-order conditional estimation with interaction 
(FOCEI) method in NONMEM was employed for model runs.
A stepwise forward selection and backward elimination approach was used for both paclitaxel and carbopla-
tin modelling. Generally, a base model without any covariates was developed. Random effects were treated as 
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lognormal in distribution. Residual error was modelled as additive error, proportional error or a combination of 
these two. One, two or three compartment models were tested when necessary. After a best base model was found, 
covariate modeling was then performed. The covariates examined in the model included age, weight, GFR, albu-
min, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), haemoglobin, white blood 
cell (WBC) count, absolute neutrophil count (ANC) and platelet. Final model was assessed by a visual predictive 
check, comparing observed concentration vs. time data and the 90% confidence interval generated using 500 
simulated concentration–time data sets.
One compartment model with proportional and additive residual error described carboplatin concentra-
tion data very well. The final model for paclitaxel is a 3-compartment model with proportional residual error46. 
Paclitaxel clearance is non-linear and it is not clear which time points are the most indicative of clinically impor-
tant paclitaxel clearance. Time of paclitaxel concentration >0.05 µmol/L (TC>0.05) has been reported to be asso-
ciated with both haematological toxicity and chemotherapy response and survival14, simulation was therefore 
performed to obtain TC>0.05 by introducing more frequent sampling schedules in the dataset.
Haematological toxicity assessment. Baseline full blood counts (FBCs) were measured within 14 
days prior to cycle one chemotherapy. Nadir FBCs were measured on day 14 ± 3 after cycle one chemotherapy. 
Haematological toxicities were assessed by relative neutropenia and thrombocytopenia, defined as the percentage 
reduction of nadir absolute neutrophil counts and platelet counts compared with baseline.
DNA extraction and genotyping. DNA was extracted from whole blood using DNA Mini Kit (Qiagen, 
GmbH, Hilden, Germany). A total of 719,665 SNPs was genotyped on the Australian and Dutch samples using 
Illumina Human OmniExpress arrays (Illumina Inc, San Diego, CA USA). The following quality control steps 
were applied: (1) removing samples with >5% missing genotypes; (2) excluding any SNP with less than 1% 
MAF; (3) excluding any SNP that failed the Hardy-Weinberg Equilibrium (HWE) test at the significance level 
of P = 1 × 10–7; (4) excluding the SNPs with MAF > 5% when the per SNP no-call rate >5%, and SNPs with 
MAF < 5% when the per SNP no-call rate >1%. One Australian patient was removed from analysis due to low 
genotyping rate (~75%). A total of 610 255 autosomal SNPs were retained after quality control. In addition, we 
checked samples for cryptic relatedness using the software PLINK47 and genetic ancestry using EIGENSTRAT48. 
We confirmed that self-reported ethnicities were concordant with genetic ancestries for all samples.
Statistical analysis. Linear regression was used to test the association between each SNP and the trait of 
interest, both adjusted and unadjusted for corresponding covariates, using PLINK47. Because meta-analysis 
has been shown to be more efficient than replication-based analysis49, we performed separate analysis within 
each population and then ran meta-analysis combining results from different populations weighted by sample 
sizes using METAL50. P values < 1 × 10−5 were considered as putative associations, and P values < 5 × 10−8 were 
regarded as genome-wide significance.
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